INOZYME PHARMA INC. -

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

26 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

19 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

27 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at the Jefferies Healthcare Conference

02 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

09 May 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 May 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

14 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer

04 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

22 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

01 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

16 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023

06 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

09 Jan 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency

05 Dec 2022 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference

01 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

10 Nov 2022 08:30:01 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate in Upcoming Investor Conferences

07 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial

03 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

31 Oct 2022 07:30:00 By Nasdaq GlobeNewswire